Suzuki D, Flahou C, Yoshikawa N, Stirblyte I, Hayashi Y, Sawaguchi A, et al. iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity. Stem Cell Reports. 2020;14:49-59 pubmed publisher

Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed publisher

Wang C, Choy F, Sanny A, Murakami T, Tan A, Lam K. An Inhibitory Role for Human CD96 Endodomain in T Cell Anti-Tumor Responses. Cells. 2023;12: pubmed publisher

Gerace D, Zhou Q, Kenty J, Veres A, Sintov E, Wang X, et al. Engineering human stem cell-derived islets to evade immune rejection and promote localized immune tolerance. Cell Rep Med. 2023;4:100879 pubmed publisher

Khan K, Ponce de León J, Benguigui M, Xu P, Chow A, Cruz Munoz W, et al. Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer. NPJ Breast Cancer. 2020;6:29 pubmed publisher

Friedman G, Bernstock J, Chen D, Nan L, Moore B, Kelly V, et al. Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Sci Rep. 2018;8:13930 pubmed publisher

Friedman G, Moore B, Nan L, Kelly V, Etminan T, Langford C, et al. Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. Neuro Oncol. 2016;18:227-35 pubmed publisher

Gillory L, Megison M, Stewart J, Mroczek Musulman E, Nabers H, Waters A, et al. Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma. PLoS ONE. 2013;8:e77753 pubmed publisher